| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers D > Headlines for DelMar Pharmaceuticals, Inc. > News item |
DelMar Pharmaceuticals to price $10 million public sale of units
Maxim Group LLC and Roth Capital Partners are the bookrunners for deal
By Devika Patel
Knoxville, Tenn., April 10 – DelMar Pharmaceuticals, Inc. will conduct a $10 million public offering of units with a 45-day greenshoe, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company has registered up to $12.65 million of stock.
The company will sell units of common shares and warrants.
Maxim Group LLC and Roth Capital Partners are the bookrunners.
Proceeds will be used for research and drug development, working capital and general corporate purposes.
The drug developer is based in Vancouver, B.C.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.